mash novo nordisk - Search News

Order byBest matchMost fresh

News

Novo Nordisk, liver

Fierce Pharma · 1d

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

Continue reading

· 4d · on MSN

Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH

· 1d · on MSN

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

Zacks.com on MSN15h

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results